No Data
Johnson & Johnson Says Lung Cancer Study on Rybrevant Plus Lazcluze Suggests Potential for More Durable Disease Control
Johnson & Johnson On Pace for Largest Percent Decrease Since May 2025 -- Data Talk
Express News | Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze® (Lazertinib) Demonstrates Prolonged Clinical Benefit as a First-Line Treatment for Atypical Egfr-Mutated Non-Small Cell Lung Cancer
FDA to Cut Animal Testing in Cancer Drug Development
TD Cowen Initiates Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $250
4 Stocks to Watch on Friday: JNJ, UNH, COST, and ADSK